Skip to content

Search

Showing results for "mental health aboriginal"

Understanding how viral infection in early life impacts on lung function in adulthood

Alexander David Deborah Larcombe Martino Strickland BScEnv (Hons) PhD BSc PhD PhD Honorary Research Fellow Head, Chronic Diseases Research Head,

Other VTG studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Clostridium difficile

Respiratory Syncytial Virus (RSV) studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Respiratory Syncytial

Our patrons

The Kids Research Institute Australia thrives thanks to our patrons. Their unwavering support propels groundbreaking research for children's health.

Kids are not small adults, Identifying age-dependent drug targets in paediatric oncology

Cancers in children are very different to cancers in adults. However, most therapeutic strategies are designed explicitly for adult cancers, and then used in children if proven safe.

Characterisation of invasive Group B Streptococcus in Western Australian infants over a 15-year period

Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

Pathogenesis of obstructive sleep apnoea

Lea-Ann Peter Ruth Kirkham Richmond Thornton PhD MBBS MRCP(UK) FRACP PhD Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,

Research to see if AI can speed up therapy for people with antibiotic-resistant bacterial infections

Researchers from the Wal-yan Respiratory Research Centre are aiming to combine artificial intelligence with natural, infection-fighting viruses to help save lives from an increasingly common medical emergency found in hospitals.

Phage therapy for compassionate use

"Compassionate Use" treatments are novel treatments not widely available to everyone, but ones that holds great promise for potentially becoming a widely used treatment in the future.

Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia

Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children.